Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRS044
MIFTS: 60

Breast Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Breast Adenocarcinoma

About this section

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 12 29 6 15 73
Mammary Adenocarcinoma 12 73
Adenocarcinoma of Breast 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3458
NCIt 50 C5214
Sources

Summaries for Breast Adenocarcinoma

About this section
Disease Ontology : 12 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to inflammatory breast carcinoma and mammary paget's disease. An important gene associated with Breast Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Paclitaxel and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, t cells and bone, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Breast Adenocarcinoma

About this section

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 inflammatory breast carcinoma 32.1 EGFR ERBB2 ESR1
2 mammary paget's disease 32.1 EGFR ERBB2 ESR1
3 breast medullary carcinoma 32.0 ERBB2 ESR1
4 adenocarcinoma 31.7 AKT1 EGF EGFR ERBB2 H19 KRAS
5 cystadenocarcinoma 30.2 AKT1 ERBB2 PIK3CA TP53
6 squamous cell carcinoma 30.2 AKT1 EGF EGFR ERBB2 H19 PIK3CA
7 lung squamous cell carcinoma 30.0 AKT1 EGFR KRAS PIK3CA TP53
8 glioma 29.9 BAX CDKN1A EGF EGFR ERBB2 H19
9 gastric adenocarcinoma 29.8 AKT1 BAX EGF EGFR ERBB2 H19
10 neuroblastoma 29.8 AKT1 CASP9 CYCS H19 PARP1 PIK3CA
11 hepatocellular carcinoma 29.5 AKT1 BAX CASP9 CDKN1A EGFR H19
12 prostate cancer 29.2 AKT1 BAX CASP9 CDKN1A CYCS EGF
13 colorectal cancer 29.1 AKT1 BAX CASP9 CDKN1A CYCS EGF
14 breast cancer 28.6 AKT1 BAX CASP9 CDKN1A CYCS EGF
15 breast signet ring cell adenocarcinoma 11.1
16 breast mucinous carcinoma 11.1
17 breast secretory carcinoma 11.1
18 glycogen-rich clear cell breast carcinoma 11.1
19 acinic cell breast carcinoma 11.1
20 breast apocrine carcinoma 11.1
21 oncocytic breast carcinoma 11.1
22 uterine corpus serous adenocarcinoma 10.4 ERBB2 PIK3CA TP53
23 uterine body mixed cancer 10.4 ERBB2 PIK3CA TP53
24 adult hepatocellular carcinoma 10.4 EGF PIK3CA TP53
25 anal squamous cell carcinoma 10.4 AKT1 PIK3CA TP53
26 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.4 KRAS PIK3CA TP53
27 serous cystadenocarcinoma 10.4 AKT1 ERBB2 PIK3CA TP53
28 breast benign neoplasm 10.4 ERBB2 ESR1 TP53
29 thoracic benign neoplasm 10.4 ERBB2 ESR1 TP53
30 breast intraductal proliferative lesion 10.4 EGFR ERBB2
31 barrett's adenocarcinoma 10.4 ERBB2 KRAS TP53
32 glassy cell carcinoma of the cervix 10.4 ERBB2 ESR1
33 carcinosarcoma 10.4 ERBB2 KRAS PIK3CA TP53
34 ovarian clear cell carcinoma 10.4 KRAS PIK3CA TP53
35 bile duct adenocarcinoma 10.4 AKT1 KRAS TP53
36 microglandular adenosis 10.4 EGFR ERBB2 TP53
37 uterine corpus cancer 10.4 ERBB2 ESR1 PIK3CA TP53
38 fallopian tube carcinoma 10.4 ERBB2 ESR1 TP53
39 brain ependymoma 10.4 EGFR TP53
40 pulmonary blastoma 10.4 EGFR KRAS TP53
41 breast scirrhous carcinoma 10.4 EGFR ERBB2 ESR1
42 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
43 primary peritoneal carcinoma 10.4 EGFR ERBB2 TP53
44 breast squamous cell carcinoma 10.4 EGFR ERBB2 PIK3CA TP53
45 suppressor of tumorigenicity 3 10.4 BAX CDKN1A TP53
46 ovary adenocarcinoma 10.3 BAX ERBB2 KRAS PIK3CA TP53
47 bladder disease 10.3 AKT1 ERBB2 MMP9 TP53
48 mucinous lung adenocarcinoma 10.3 EGFR ERBB2 KRAS
49 female breast cancer 10.3 ERBB2 ESR1 TP53
50 ovarian serous cystadenocarcinoma 10.3 AKT1 BAX ERBB2 PIK3CA TP53

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma
Sources

Symptoms & Phenotypes for Breast Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.32 EGFR KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.32 KRAS
3 Decreased viability GR00221-A-1 10.32 AKT1 EGFR ESR1 KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.32 AKT1 ESR1 KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.32 AKT1 ERBB2
6 Decreased viability GR00221-A-4 10.32 AKT1 EGFR ESR1 PIK3CA ERBB2
7 Decreased viability GR00301-A 10.32 KRAS
8 Decreased viability GR00381-A-1 10.32 KRAS
9 Decreased viability GR00402-S-2 10.32 AKT1 EGFR ESR1 KRAS PIK3CA ERBB2
10 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 AKT1 BAX CASP9 CDKN1A SLC22A18 TNF
11 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 AKT1 BAX CASP9 CDKN1A SLC22A18 TNF
12 Decreased HIV-LTR-beta-galactosidase protein expression GR00224-A-1 9.46 AKT1 CYCS MMP9 RB1CC1

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AKT1 BAX CASP9 CDKN1A CYCS EGFR
2 growth/size/body region MP:0005378 10.51 AKT1 BAX CASP9 CDKN1A CYCS EGF
3 immune system MP:0005387 10.48 AKT1 BAX CASP9 CDKN1A CYCS EGF
4 behavior/neurological MP:0005386 10.47 AKT1 BAX CDKN1A CYCS ERBB2 ESR1
5 endocrine/exocrine gland MP:0005379 10.47 AKT1 BAX CASP9 CDKN1A CYCS EGF
6 cardiovascular system MP:0005385 10.44 AKT1 CASP9 CDKN1A CYCS EGFR ERBB2
7 hematopoietic system MP:0005397 10.44 AKT1 BAX CASP9 CDKN1A CYCS EGFR
8 homeostasis/metabolism MP:0005376 10.43 AKT1 BAX CDKN1A EGFR ERBB2 ESR1
9 mortality/aging MP:0010768 10.42 AKT1 BAX CASP9 CDKN1A CYCS EGFR
10 embryo MP:0005380 10.41 AKT1 CASP9 CDKN1A CYCS EGFR ERBB2
11 integument MP:0010771 10.41 AKT1 CDKN1A EGF EGFR ERBB2 ESR1
12 craniofacial MP:0005382 10.31 CASP9 CDKN1A CYCS EGFR ERBB2 FOS
13 nervous system MP:0003631 10.31 AKT1 BAX CASP9 CDKN1A CYCS EGFR
14 digestive/alimentary MP:0005381 10.3 CDKN1A EGF EGFR ERBB2 ESR1 KRAS
15 muscle MP:0005369 10.29 AKT1 BAX CDKN1A EGFR ERBB2 ESR1
16 neoplasm MP:0002006 10.27 AKT1 BAX CDKN1A EGFR ERBB2 ESR1
17 limbs/digits/tail MP:0005371 10.26 BAX CDKN1A EGFR ERBB2 ESR1 FOS
18 adipose tissue MP:0005375 10.18 AKT1 CDKN1A EGFR ESR1 PIK3CA TNF
19 reproductive system MP:0005389 10.13 AKT1 BAX CDKN1A EGF EGFR ERBB2
20 hearing/vestibular/ear MP:0005377 10.12 BAX CDKN1A EGFR FOS KRAS PARP1
21 liver/biliary system MP:0005370 10.11 AKT1 CDKN1A EGFR ESR1 KRAS RB1CC1
22 no phenotypic analysis MP:0003012 10.1 CDKN1A EGFR ESR1 KRAS PARP1 PIK3CA
23 normal MP:0002873 10.07 AKT1 EGF EGFR ERBB2 ESR1 FOS
24 respiratory system MP:0005388 9.93 AKT1 BAX CASP9 CDKN1A EGFR ERBB2
25 renal/urinary system MP:0005367 9.92 BAX CDKN1A EGFR ESR1 KRAS MMP9
26 skeleton MP:0005390 9.8 AKT1 BAX CDKN1A CYCS EGFR ERBB2
27 vision/eye MP:0005391 9.4 BAX CDKN1A EGF EGFR FOS KRAS
Sources

Drugs & Therapeutics for Breast Adenocarcinoma

About this section

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33069-62-4 36314
2
Letrozole Approved, Investigational Phase 3,Phase 2 112809-51-5 3902
3
Tamoxifen Approved Phase 3 10540-29-1 2733526
4
Zoledronic acid Approved Phase 3 118072-93-8 68740
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
8
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
9
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
10
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
11
Atezolizumab Approved, Investigational Phase 3,Phase 2 1380723-44-3
12
Goserelin Approved Phase 3 65807-02-5 47725 5311128
13
Pertuzumab Approved Phase 3,Phase 2 145040-37-5, 380610-27-5 2540
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16
Entinostat Investigational Phase 3,Phase 1 209783-80-2
17 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
18 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
19 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
20 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunologic Factors Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
22 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunoglobulins Phase 3,Phase 2,Phase 1
24 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
25 Antibodies Phase 3,Phase 2,Phase 1
26 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Hormonal Phase 3,Phase 2
29 Aromatase Inhibitors Phase 3,Phase 2
30 Steroid Synthesis Inhibitors Phase 3,Phase 2
31 Estrogen Receptor Antagonists Phase 3,Phase 2
32 Selective Estrogen Receptor Modulators Phase 3
33 Estrogen Receptor Modulators Phase 3
34 Anticoagulants Phase 3
35 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
36 Chelating Agents Phase 3
37 Estrogen Antagonists Phase 3,Phase 2
38 Citrate Phase 3
39 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
40 Calcium, Dietary Phase 3
41 Bone Density Conservation Agents Phase 3
42 Diphosphonates Phase 3
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
44 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
45 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
46 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Histone Deacetylase Inhibitors Phase 3,Phase 1
49
Hydroxychloroquine Approved Phase 2 118-42-3 3652
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
2 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Completed NCT00869206 Phase 3 zoledronic acid
3 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer Recruiting NCT03337724 Phase 2, Phase 3 Ipatasertib;Paclitaxel;Placebo
4 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
5 Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer Active, not recruiting NCT02037529 Phase 3 Eribulin Mesylate;Paclitaxel
6 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Active, not recruiting NCT02115282 Phase 3 Entinostat;Exemestane;Goserelin Acetate
7 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
8 Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00005970 Phase 3 Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
9 Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer Not yet recruiting NCT03199885 Phase 3 Atezolizumab;Paclitaxel
10 Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients Unknown status NCT01292408 Phase 2 Hydrochloroquine
11 Study of MDX-010 in Stage IV Breast Cancer Completed NCT00083278 Phase 2 MDX-010
12 Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer Completed NCT00039520 Phase 2 docetaxel;sulindac
13 Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer Completed NCT00019916 Phase 1, Phase 2
14 Chemotherapy in Treating Women With Metastatic Breast Cancer Completed NCT00004046 Phase 2 exatecan mesylate
15 A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer Completed NCT02301988 Phase 2 Ipatasertib;Paclitaxel;Placebo
16 Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes Completed NCT01693549 Phase 2 Cabazitaxel
17 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
18 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility Completed NCT00591851 Phase 2 AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
19 IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma Recruiting NCT02614833 Phase 2 Placebo;Paclitaxel
20 Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Recruiting NCT01928589 Phase 1, Phase 2
21 Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Recruiting NCT02894398 Phase 2 Palbociclib;Letrozole;Anastrozole;Exemestane;Fulvestrant
22 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Recruiting NCT03106415 Phase 1, Phase 2 Binimetinib
23 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
24 Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Recruiting NCT01697293 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
25 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Recruiting NCT03250676 Phase 1, Phase 2 H3B-6545
26 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
27 Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer Recruiting NCT02530489 Phase 2 MPDL3280A;Nab-paclitaxel
28 CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer Active, not recruiting NCT02067741 Phase 2 CR1447
29 A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread Active, not recruiting NCT02322814 Phase 2 Cobimetinib;Paclitaxel;Placebo;Atezolizumab;Nab-Paclitaxel
30 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients Active, not recruiting NCT01097642 Phase 2 Cetuximab;Ixabepilone
31 Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Active, not recruiting NCT01730833 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
32 Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation Active, not recruiting NCT02282345 Phase 2 Talazoparib
33 Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 Active, not recruiting NCT01593020 Phase 2 Paclitaxel;Eribulin;5-Fluorouracil;Epirubicin;Cyclophosphamide;Doxorubicin
34 Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer Terminated NCT00074269 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methotrexate
35 Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Withdrawn NCT03666819 Phase 2
36 Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer Unknown status NCT00009763 Phase 1 cyclosporine;paclitaxel
37 Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast Completed NCT02204046 Phase 1 BIWA 4
38 Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Completed NCT00003761 Phase 1
39 Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer Completed NCT01502592 Phase 1
40 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
41 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer Recruiting NCT02824575 Phase 1 Rebastinib;Paclitaxel;Eribulin Mesylate
42 Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) Recruiting NCT01724606 Phase 1 Sorafenib
43 Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Recruiting NCT03432741 Phase 1 Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
44 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Recruiting NCT02453620 Phase 1 Entinostat
45 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
46 Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma Recruiting NCT02783300 Phase 1 GSK3326595.
47 Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer Not yet recruiting NCT03749850 Phase 1 LTLD;Cyclophosphamide
48 Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Terminated NCT00071942 Phase 1
49 Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
50 Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer Completed NCT00640861 Early Phase 1

Search NIH Clinical Center for Breast Adenocarcinoma

Sources

Genetic Tests for Breast Adenocarcinoma

About this section

Genetic tests related to Breast Adenocarcinoma:

# Genetic test Affiliating Genes
1 Breast Adenocarcinoma 29
Sources

Anatomical Context for Breast Adenocarcinoma

About this section

MalaCards organs/tissues related to Breast Adenocarcinoma:

41
Breast, T Cells, Bone, Lung, Prostate, Brain, Colon
Sources

Publications for Breast Adenocarcinoma

About this section

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 892)
# Title Authors Year
1
Lycopene-rich extract from red guava (Psidium guajava L.) displays cytotoxic effect against human breast adenocarcinoma cell line MCF-7 via an apoptotic-like pathway. ( 29433206 )
2018
2
Assessment of synergistic effect of combining hyperthermia with irradiation and calcium carbonate nanoparticles on proliferation of human breast adenocarcinoma cell line (MCF-7 cells). ( 29616844 )
2018
3
Chitosan-Cellulose Multifunctional Hydrogel Beads: Design, Characterization and Evaluation of Cytocompatibility with Breast Adenocarcinoma and Osteoblast Cells. ( 29315214 )
2018
4
Improving of Anticancer Activity and Solubility of Cisplatin by Methylglycine and Methyl Amine Ligands Against Human Breast Adenocarcinoma Cell Line. ( 29516403 )
2018
5
Baicalein disturbs the morphological plasticity and motility of breast adenocarcinoma cells depending on the tumor microenvironment. ( 29667279 )
2018
6
Gold and Silver Nanoparticles Biomimetically Synthesized Using Date Palm Pollen Extract-Induce Apoptosis and Regulate p53 and Bcl-2 Expression in Human Breast Adenocarcinoma Cells. ( 29552710 )
2018
7
Raman Spectroscopic Signatures Reveal Distinct Biochemical and Temporal Changes in Irradiated Human Breast Adenocarcinoma Xenografts. ( 29474157 )
2018
8
Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-I_I^, blocking angiogenesis and regulation of mitochondrial apoptotic pathway. ( 29775573 )
2018
9
Cucumol B, a new triterpene benzoate from Cucumis melo seeds with cytotoxic effect toward ovarian and human breast adenocarcinoma. ( 29947257 )
2018
10
FMSP-Nanoparticles Induced Cell Death on Human Breast Adenocarcinoma Cell Line (MCF-7 Cells): Morphometric Analysis. ( 29882888 )
2018
11
Gadopentatic acid affects in vitro proliferation and doxorubicin response in human breast adenocarcinoma cells. ( 29728885 )
2018
12
Enhancing the Therapeutic Efficacy of Tamoxifen Citrate Loaded Span-Based Nano-Vesicles on Human Breast Adenocarcinoma Cells. ( 29470829 )
2018
13
Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study. ( 29138806 )
2018
14
Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo. ( 29842818 )
2018
15
Induction of Apoptosis and Cytotoxicity by Raphasatin in Human Breast Adenocarcinoma MCF-7 Cells. ( 30486382 )
2018
16
Death Mechanism of Breast Adenocarcinoma Cells Caused by BRET-Induced Cytotoxicity of miniSOG Depends on the Intracellular Localization of the NanoLuc-miniSOG Fusion Protein. ( 30397895 )
2018
17
Zerumbone-Loaded Nanostructured Lipid Carrier Induces Apoptosis of Canine Mammary Adenocarcinoma Cells. ( 30410940 )
2018
18
Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells. ( 30352078 )
2018
19
68Ga-Prostate-Specific Membrane Antigen PET/CT and 18F-FDG PET/CT of Primary Signet Ring Cell Breast Adenocarcinoma. ( 30247208 )
2018
20
Paclitaxel delivery system based on poly(lactide-co-glycolide) microparticles and chitosan thermo-sensitive gel for mammary adenocarcinoma treatment. ( 30182425 )
2018
21
TPEN exerts antitumor efficacy in murine mammary adenocarcinoma through an H2O2 signaling mechanism dependent on caspase-3. ( 29697031 )
2018
22
Metabolomics analysis of the potential anticancer mechanism of annonaceous acetogenins on a multidrug resistant mammary adenocarcinoma cell. ( 29750943 )
2018
23
Association of surgical approach with complication rate, progression-free survival time, and disease-specific survival time in cats with mammary adenocarcinoma: 107 cases (1991-2014). ( 29772965 )
2018
24
Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells. ( 28270066 )
2017
25
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. ( 29147603 )
2017
26
Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro. ( 29179603 )
2017
27
Vanadium(III)-l-cysteine enhances the sensitivity of murine breast adenocarcinoma cells to cyclophosphamide by promoting apoptosis and blocking angiogenesis. ( 28466788 )
2017
28
Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line. ( 28092843 )
2017
29
Efficient T3P(Ar) mediated synthesis, differential cytotoxicity and apoptosis induction by indolo-triazolo-thiadiazoles in human breast adenocarcinoma cells. ( 28235427 )
2017
30
The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60]fullerene derivative in a murine orthotopic model of breast adenocarcinoma. ( 28527736 )
2017
31
hsa-miR-1973 MicroRNA is Significantly and Differentially Expressed in MDA-MB-231 Cells of Breast Adenocarcinoma and Xenografts Derived from the Tumor. ( 28948560 )
2017
32
HER2/Topoisomerase IIa co-amplified breast adenocarcinoma "mirror" cases with different Topoisomerase IIa expression patterns. ( 28534385 )
2017
33
Remote Development of Tumor-to-Tumor Metastasis of Breast Adenocarcinoma in a Renal Oncocytoma. ( 28551171 )
2017
34
Persian Gulf Jellyfish (Cassiopea andromeda) Venom Fractions Induce Selective Injury and Cytochrome C Release in Mitochondria Obtained from Breast Adenocarcinoma Patients ( 28240847 )
2017
35
Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro. ( 28461972 )
2017
36
Phenolics from Rubus fairholmianus induces cytotoxicity and apoptosis in human breast adenocarcinoma cells. ( 28803117 )
2017
37
Biotransport kinetics and intratumoral biodistribution of malonodiserinolamide-derivatized [60]fullerene in a murine model of breast adenocarcinoma. ( 29180866 )
2017
38
Derivatives of alkyl gallate triphenylphosphonium exhibit antitumor activity in a syngeneic murine model of mammary adenocarcinoma. ( 28647477 )
2017
39
Cytokine production in mammary adenocarcinoma and its microenvironmental cells in patients with or without metastases in regional lymph nodes. ( 28745079 )
2017
40
In vitro and in vivo antitumour effects of phenylboronic acid against mouse mammary adenocarcinoma 4T1 and squamous carcinoma SCCVII cells. ( 29072095 )
2017
41
Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. ( 27338760 )
2016
42
Inhibitory and Cytotoxic Activities of Chrysin on Human Breast Adenocarcinoma Cells by Induction of Apoptosis. ( 27761071 )
2016
43
Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma. ( 27752764 )
2016
44
Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells. ( 27013580 )
2016
45
HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. ( 27245202 )
2016
46
Phyto-synthesis of silver nanoparticles using Alternanthera tenella leaf extract: an effective inhibitor for the migration of human breast adenocarcinoma (MCF-7) cells. ( 26801668 )
2016
47
184AA3: a xenograft model of ER+ breast adenocarcinoma. ( 26661596 )
2016
48
Role of Glutathione System Redox Potential in Apoptosis Dysregulation in MCF-7 Breast Adenocarcinoma. ( 26750929 )
2016
49
A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition. ( 27551492 )
2016
50
SERS-active Au/SiO2 clouds in powder for rapid ex vivo breast adenocarcinoma diagnosis. ( 27375955 )
2016
Sources

Variations for Breast Adenocarcinoma

About this section

ClinVar genetic disease variations for Breast Adenocarcinoma:

6 (show all 22)
# Gene Variation Type Significance SNP ID Assembly Location
1 RB1CC1 NG_015833.1: g.34008_95699del61692 deletion Pathogenic GRCh38 Chromosome 8, 52623768: 52685459
2 RB1CC1 NG_015833.1: g.34008_95699del61692 deletion Pathogenic GRCh37 Chromosome 8, 53536328: 53598019
3 RB1CC1 NG_015833.1: g.57807_94706del36900 deletion Pathogenic GRCh38 Chromosome 8, 52624761: 52661660
4 RB1CC1 NG_015833.1: g.57807_94706del36900 deletion Pathogenic GRCh37 Chromosome 8, 53537321: 53574220
5 SLC22A18 NM_002555.5(SLC22A18): c.864_865insNC_000011.10: g.2919738_2919848 insertion Pathogenic
6 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
7 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
8 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
9 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
10 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
11 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
12 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
13 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
16 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
17 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
18 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
21 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
22 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
Sources

Expression for Breast Adenocarcinoma

About this section
Search GEO for disease gene expression data for Breast Adenocarcinoma.
Sources

Pathways for Breast Adenocarcinoma

About this section

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 14.34 AKT1 CASP9 CDKN1A EGF EGFR ERBB2
2
Innate Immune System 66
Show member pathways
 14.21 AKT1 CASP9 CDKN1A EGF EGFR ERBB2
3
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 14.06 AKT1 BAX CASP9 CYCS EGF EGFR
4
ERK Signaling 64
Show member pathways
 14.04 AKT1 BAX CASP9 CDKN1A CYCS EGF
5
Gene Expression 66
Show member pathways
 13.96 AKT1 BAX CDKN1A CYCS EGFR ERBB2
6
GPCR Pathway 64
Show member pathways
 13.91 AKT1 CDKN1A EGF EGFR ERBB2 ESR1
7
PEDF Induced Signaling 64
Show member pathways
 13.87 AKT1 BAX CASP9 CDKN1A EGFR ERBB2
8
TGF-Beta Pathway 64
Show member pathways
 13.74 AKT1 BAX CDKN1A EGF EGFR ERBB2
9
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.7 AKT1 BAX CASP9 CYCS KRAS PIK3CA
10
Developmental Biology 66
Show member pathways
 13.65 AKT1 EGF EGFR ERBB2 KRAS MMP9
11
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.63 AKT1 CASP9 CDKN1A EGF EGFR ERBB2
12
Akt Signaling 64
Show member pathways
 13.61 AKT1 BAX CASP9 CDKN1A EGF EGFR
13
Cytokine Signaling in Immune system 66
Show member pathways
 13.56 AKT1 CDKN1A EGF EGFR ERBB2 FOS
14
PAK Pathway 64
Show member pathways
 13.51 AKT1 BAX CASP9 EGF EGFR ERBB2
15
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.46 AKT1 EGF EGFR ERBB2 ESR1 FOS
16
IL-2 Pathway 64
Show member pathways
 13.43 AKT1 BAX CYCS EGF EGFR ERBB2
17
PI3K/AKT activation 66
Show member pathways
 13.32 AKT1 CASP9 CDKN1A EGF EGFR ERBB2
18
Circadian entrainment 37
Show member pathways
 13.22 AKT1 EGFR ESR1 FOS KRAS MMP9
19
PI3K-Akt signaling pathway 37
Show member pathways
 13.19 AKT1 BAX CASP9 CDKN1A EGF EGFR
20
Human cytomegalovirus infection 37
Show member pathways
 13.19 AKT1 BAX CASP9 CDKN1A CYCS EGFR
21
G-Beta Gamma Signaling 64
Show member pathways
 13.18 AKT1 EGF EGFR FOS KRAS MMP9
22
Development Angiotensin activation of ERK 22
Show member pathways
 13.15 AKT1 CASP9 CYCS EGFR FOS KRAS
23
Regulation of TP53 Activity 66
Show member pathways
 13.12 AKT1 BAX CDKN1A CYCS FOS TP53
24
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.11 AKT1 EGF EGFR ERBB2 FOS KRAS
25
Focal Adhesion 1 37
Show member pathways
 13.1 AKT1 EGF EGFR ERBB2 FOS KRAS
26
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13.03 AKT1 CASP9 EGFR ERBB2 KRAS PIK3CA
27
Influenza A 37
Show member pathways
 13.01 AKT1 CASP9 CYCS FOS PIK3CA TNF
28
MAPK signaling pathway 37 1
13 AKT1 CASP9 EGF EGFR ERBB2 FOS
29
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.96 AKT1 CDKN1A FOS KRAS PIK3CA TNF
30
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.95 AKT1 CASP9 CDKN1A EGF EGFR ERBB2
31
Apoptosis Modulation and Signaling 1
Show member pathways
 12.95 AKT1 BAX CASP9 CDKN1A CYCS FOS
32
Chks in Checkpoint Regulation 64
Show member pathways
 12.92 BAX CASP9 CDKN1A CYCS ESR1 PARP1
33
Development HGF signaling pathway 22
Show member pathways
 12.91 AKT1 BAX CASP9 CYCS ERBB2 ESR1
34
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.9 AKT1 CASP9 CYCS EGFR FOS KRAS
35
Pathways in cancer 37
12.89 AKT1 BAX CASP9 CDKN1A CYCS EGF
36
4-1BB Pathway 64
Show member pathways
 12.88 AKT1 BAX CASP9 CYCS EGF EGFR
37
TNFR1 Pathway 64
Show member pathways
 12.88 AKT1 BAX CASP9 CDKN1A CYCS EGFR
38
Ras signaling pathway 37
Show member pathways
 12.87 AKT1 EGF EGFR KRAS PIK3CA
39
Vascular smooth muscle contraction 37
Show member pathways
 12.87 AKT1 CDKN1A EGFR FOS KRAS
40
Gastric cancer 37
Show member pathways
 12.85 AKT1 BAX CDKN1A EGF EGFR ERBB2
41
TRAF Pathway 64
Show member pathways
 12.84 AKT1 CASP9 CYCS FOS PIK3CA TNF
42
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.81 AKT1 BAX CASP9 CYCS EGF EGFR
43
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.8 AKT1 CASP9 FOS KRAS PIK3CA TNF
44
MicroRNAs in cancer 37
12.76 CDKN1A EGFR ERBB2 KRAS MMP9 PIK3CA
45
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.74 AKT1 EGFR ERBB2 KRAS PIK3CA TNF
46
Prolactin Signaling Pathway 1 37
Show member pathways
 12.73 AKT1 BAX ERBB2 ESR1 FOS KRAS
47
Immune response IL-23 signaling pathway 22
Show member pathways
 12.71 AKT1 BAX CASP9 CDKN1A EGFR ERBB2
48
Endometrial cancer 37
Show member pathways
 12.71 AKT1 BAX CASP9 CDKN1A CYCS EGF
49
ErbB signaling pathway 1 37
Show member pathways
 12.69 AKT1 CDKN1A EGF EGFR ERBB2 FOS
50
Apoptosis Pathway 72
Show member pathways
 12.68 AKT1 BAX CASP9 EGFR ERBB2 KRAS
Sources

GO Terms for Breast Adenocarcinoma

About this section

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 AKT1 BAX CASP9 CDKN1A EGFR ERBB2
2 protein-containing complex GO:0032991 9.17 AKT1 CASP9 CDKN1A EGFR ESR1 PARP1

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.96 CASP9 CDKN1A EGFR FOS
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.93 AKT1 ESR1 TNF TNFSF11
3 phosphatidylinositol phosphorylation GO:0046854 9.91 EGF EGFR ERBB2 ESR1 PIK3CA
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.9 BAX CASP9 TNF
5 positive regulation of JNK cascade GO:0046330 9.9 RB1CC1 TNF TNFSF11
6 positive regulation of cell growth GO:0030307 9.9 AKT1 EGFR ERBB2
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.89 AKT1 EGFR PIK3CA TNF
8 cellular response to organic cyclic compound GO:0071407 9.88 AKT1 CASP9 TNF
9 Ras protein signal transduction GO:0007265 9.88 CDKN1A KRAS TP53
10 response to glucocorticoid GO:0051384 9.88 CDKN1A KRAS TNF
11 glucose metabolic process GO:0006006 9.88 AKT1 PIK3CA TNF
12 liver development GO:0001889 9.88 EGFR KRAS PIK3CA RB1CC1
13 cellular response to growth factor stimulus GO:0071363 9.87 AKT1 EGFR ERBB2
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 AKT1 EGFR TNF
15 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.87 BAX CDKN1A TP53
16 positive regulation of protein localization to plasma membrane GO:1903078 9.86 AKT1 EGFR TNF
17 positive regulation of fibroblast proliferation GO:0048146 9.86 CDKN1A EGFR ESR1
18 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.85 BAX CASP9 TNF
19 cellular response to epidermal growth factor stimulus GO:0071364 9.85 AKT1 EGFR ERBB2
20 negative regulation of Notch signaling pathway GO:0045746 9.84 AKT1 EGF EGFR
21 protein kinase B signaling GO:0043491 9.84 AKT1 PIK3CA TNF
22 epidermal growth factor receptor signaling pathway GO:0007173 9.84 AKT1 EGF EGFR PIK3CA
23 phosphatidylinositol 3-kinase signaling GO:0014065 9.83 AKT1 ERBB2 PIK3CA
24 cellular response to UV GO:0034644 9.83 BAX CASP9 PARP1 TP53
25 regulation of cell motility GO:2000145 9.82 EGF EGFR ERBB2
26 response to gamma radiation GO:0010332 9.82 BAX PARP1 TP53
27 positive regulation of phosphorylation GO:0042327 9.8 EGF EGFR TNFSF11
28 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.8 BAX MMP9 TP53
29 positive regulation of protein phosphorylation GO:0001934 9.8 AKT1 EGFR ERBB2 KRAS MMP9 RB1CC1
30 positive regulation of osteoclast differentiation GO:0045672 9.77 FOS TNF TNFSF11
31 cellular response to cadmium ion GO:0071276 9.76 AKT1 EGFR FOS MMP9
32 mammary gland alveolus development GO:0060749 9.75 EGF ESR1 TNFSF11
33 cellular response to reactive oxygen species GO:0034614 9.73 AKT1 EGFR FOS MMP9
34 anoikis GO:0043276 9.72 AKT1 PIK3CA
35 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.72 ESR1 TP53
36 astrocyte activation GO:0048143 9.72 EGFR TNF
37 vagina development GO:0060068 9.71 BAX ESR1
38 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.71 EGFR TP53
39 response to salt stress GO:0009651 9.71 BAX TNF
40 obsolete positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.7 AKT1 EGFR
41 positive regulation of protein kinase B signaling GO:0051897 9.7 EGF EGFR ERBB2 ESR1 PIK3CA TNF
42 signal transduction by p53 class mediator GO:0072331 9.67 CDKN1A TP53
43 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.67 BAX CASP9 CYCS
44 intrinsic apoptotic signaling pathway GO:0097193 9.67 BAX CDKN1A CYCS TP53
45 response to UV-A GO:0070141 9.65 AKT1 EGFR
46 ERBB2 signaling pathway GO:0038128 9.62 EGF EGFR ERBB2 PIK3CA
47 negative regulation of ERBB signaling pathway GO:1901185 9.58 EGF EGFR ERBB2
48 positive regulation of MAP kinase activity GO:0043406 9.43 EGF EGFR ERBB2 KRAS TNF TNFSF11
49 cytokine-mediated signaling pathway GO:0019221 9.28 AKT1 CDKN1A FOS KRAS MMP9 PIK3CA
50 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 AKT1 EGFR ESR1 FOS PARP1 TNF

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.81 AKT1 BAX EGFR ERBB2 ESR1 MMP9
2 enzyme binding GO:0019899 9.77 AKT1 EGFR ESR1 PARP1 TP53
3 protein phosphatase binding GO:0019903 9.58 EGFR ERBB2 TP53
4 nitric-oxide synthase regulator activity GO:0030235 9.43 AKT1 EGFR ESR1
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.35 EGF EGFR ERBB2 ESR1 PIK3CA
6 protein kinase binding GO:0019901 9.23 AKT1 CASP9 CDKN1A EGFR ESR1 PARP1
7 protein binding GO:0005515 10.28 AKT1 BAX CASP9 CDKN1A CYCS EGF
Sources

Sources for Breast Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....